首頁
TUMS Preclinical Core Facility

7月 2026TUMS Preclinical Core Fa...的市場佔有率分析

Tehran University of Medical Sciences is the largest and most highly ranked medical university of Iran. In September 2008, Iran's Minister of Health, Treatment, and Medical Education, Lankarani, called TUMS a pioneer in research throughout the country with a noticeable lead over its peers.

科學與教育 > 生物學

域名tums.ac.ir

成立年份--

僱員> 10001

年度營收--

TUMS Preclinical Core Facility

TUMS Preclinical Core Facility（包含公司地區）

tums.ac.ir

查看更多網站流量與參與度資訊

TUMS Preclinical Core Facility的熱門網域總造訪量

了解TUMS Preclinical Core Facility市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

tums.ac.ir344.4K

透過銷售情報查看更多內容

TUMS Preclinical Core Facility的熱門網域平均造訪時長

分析TUMS Preclinical Core Facility參與度指標。

過去 3 個月平均造訪時長

子公司細目

tums.ac.ir00:01:51

透過銷售情報查看更多內容

TUMS Preclinical Core Facility的熱門網域平均頁面瀏覽量

了解TUMS Preclinical Core Facility如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

tums.ac.ir3.49

透過銷售情報查看更多內容

TUMS Preclinical Core Facility按網域劃分的熱門競爭對手

7月 2026的熱門類似網站，依相似度排名

ut.ac.ir公司名University of Tehran僱員201 - 500總部伊朗, Tehran年度營收$75M - $100M訪問總量790.9K科學與教育 > 科學與教育 - 其他

使用的熱門技術TUMS Preclinical Core Facility

这些是TUMS Preclinical Core Facility顶级域名使用的行业网站技术

付款與貨幣 (21)

PayPal

轉換與分析 (2)

Google Analytics

行動裝置 (2)

Meta Viewport

社群 (2)

Instagram

更多技術

4

檢視所有

新聞與訊號來自TUMS Preclinical Core Facility

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Tums recognized as two universities ranked among top 500 institutions in the world on Jan 1st '25.In this year's ranking, University of Tehran (335) and Tehran University of Medical Sciences (468) are the two universities ranked among top 500 institutions in the world.

新聞Tums hired Mahmoud Eshtiaghi on Mar 1st '22.Earlier in March, the Tehran University of Medical Sciences appointed Mahmoud Eshtiaghi, a maddah or religious ‘reciter’ with no medical experience, as the head of the Bahrami Children's Hospital.

新聞International Agency for Research on Cancer partners with Tums.To assess the test’s ability to detect the mutations in urine samples before any clinical symptoms of bladder cancer occur, IARC researchers collaborated with the Tehran University of Medical Sciences in Iran and the United States National Cancer Institute to design a unique pilot study within the Golestan Cohort Study.